HPTN 083: Incident Infections and Emergent Resistance in MSM and TGW Receiving Cabotegravir Long-Acting PrEP

March 6-10, 2021; Virtual
Longitudinal analysis of HIV infections, viral load, cabotegravir concentrations, and emergent resistance in HPTN 083 demonstrated the importance of prompt diagnosis and initiation of ART to avoid resistance in cases of breakthrough infection with long-acting cabotegravir as PrEP.
Format: Microsoft PowerPoint (.ppt)
File Size: 382 KB
Released: March 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Silvia Petretti on individualizing antiretroviral therapy according to patient factors from Clinical Care Options

person default Silvia Petretti Released: October 22, 2021

Clinical Care Options (CCO) expert analysis of new HIV data from IDWeek 2021, provided by expert HIV faculty

Eric S. Daar, MD Released: October 21, 2021

Slides from CCO: ART in Pregnancy: guideline recommendations and supporting data, pharmacokinetic considerations, and drug-drug interactions

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Jonah Musa, MBBS, MSCI, PhD Released: October 20, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue